BRAF and plasma cell myeloma: BRAF V600E mutations have been reported as oncogenic mutation or resistant mutation to drugs in melanoma [26, 27] and thyroid cancer [28], GIST [29], hairy cell leukemia [30], multiple myeloma [31], and pediatric metanephric tumors [32].